opiranserin + acetaminophen

Opiranserin + acetaminophen is a combination analgesic therapy being evaluated for the management of postoperative pain. Opiranserin (also known as VVZ-149) is a first-in-class dual antagonist targeting the glycine transporter type 2 (GlyT2) and the serotonin receptor 2A (5-HT2A), which are involved in pain signaling pathways in the spinal cord and peripheral tissues. Acetaminophen is a widely used non-opioid analgesic that acts primarily in the central nervous system. This combination aims to provide synergistic or additive pain relief, potentially reducing the need for opioids or NSAIDs in the postoperative setting. It has been studied in clinical trials for pain management following minimally invasive surgeries like cholecystectomy.

Other names

VVZ-149 + acetaminophenVVZ-149 + paracetamolopiranserin/acetaminophen